Rituximab mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

• Main Authors: Tobias Zrzavy (Author), Esther Daniels (Author), Niklas Stuka (Author), Dennis Weber (Author), Alexander Winkelmann (Author), Helmut Rauschka (Author), Michael Hecker (Author), Fahmy Aboulenein-Djamshidian (Author), Stefanie Meister (Author), Fritz Leutmezer (Author), Thomas Berger (Author), Gabriel Bsteh (Author), Uwe Klaus Zettl (Author), Paulus Rommer (Author)
• Format: Book
• Published: SAGE Publishing, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Rituximab (RTX), a CD20 depleting agent, is a frequently used off-label treatment for multiple sclerosis (MS), while mitoxantrone (MTX) is approved, albeit rarely used for active relapsing MS (RMS). However, observational data comparing RTX and MTX effectiveness and safety are scarce. Ob...